CoChat

HLA-DRB1*16: 01-DQB1*05 02 is a novel genetic risk factor for flupirtine-induced liver injury

Open access
Nicoletti, Paola, Werk, Anneke N., Sawle, Ashley, Shen, Yufeng, Urban, Thomas J., Coulthard, Sally A., Bjornsson, Einar S., Cascorbi, Ingolf, Floratos, Aris, Stammschulte, Thomas, Gundert-Remy, Ursula, Nelson, Matthew R., Aithal, Guruprasad P., Daly, Ann K. · 2016 · Pharmacogenetics and Genomics
Cited by 79

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Flupirtine is a nonopioid analgesic with regulatory approval in a number of European countries. Because of the risk of serious liver injury, its use is now limited to short-term pain management. We aimed to identify genetic risk factors for flupirtine-related drug-induced liver injury (DILI) as these are unknown. MATERIALS AND METHODS: Six flupirtine-related DILI patients from Germany were included in a genome-wide association study (GWAS) involving a further 614 European cases of DILI because of other drugs and 10,588 population controls. DILI was diagnosed by causality assessment and expert review. Human leucocyte antigen (HLA) and single nucleotide polymorphism genotypes were imputed from the GWAS data, with direct HLA typing performed on selected cases to validate HLA predictions. Four replication cases that were unavailable for the GWAS were genotyped by direct HLA typing, yielding an overall total of 10 flupirtine DILI cases. RESULTS: In the six flupirtine DILI cases included in the GWAS, we found a significant enrichment of the DRB1*16:01-DQB1*05:02 haplotype compared with the controls (minor allele frequency cases 0.25 and minor allele frequency controls 0.013; P=1.4 × 10(-5)). We estimated an odds ratio for haplotype carriers of 18.7 (95% confidence interval 2.5-140.5, P=0.002) using population-specific HLA control data. The result was replicated in four additional cases, also with a haplotype frequency of 0.25. In the combined cohort (six GWAS plus four replication cases), the haplotype was also significant (odds ratio 18.7, 95% confidence interval 4.31-81.42, P=6.7 × 10(-5)). CONCLUSION: We identified a novel HLA class II association for DILI, confirming the important contribution of HLA genotype towards the risk of DILI generally.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/fpc.0000000000000209

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 36

  1. Kornhuber, 1999, Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication, J Neural Transm (Vienna), 106, 857, 10.1007/s007020050206 · DOI
  2. Puls, 2011, Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases, Virchows Arch, 458, 709, 10.1007/s00428-011-1087-9 · DOI
  3. Anderson, 2011, Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting, PLoS One, 6, e25221, 10.1371/journal.pone.0025221 · DOI
  4. Douros, 2014, Flupirtine-induced liver injury – seven cases from the Berlin case–control surveillance study and review of the German spontaneous adverse drug reaction reporting database, Eur J Clin Pharmacol, 70, 453, 10.1007/s00228-013-1631-4 · DOI
  5. Michel, 2012, Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years, Br J Clin Pharmacol, 73, 821, 10.1111/j.1365-2125.2011.04138.x · DOI
  6. Douros, 2015, Drug-induced liver injury: results from the hospital-based Berlin case–control surveillance study, Br J Clin Pharmacol, 79, 988, 10.1111/bcp.12565 · DOI · Paper page
  7. Methling, 2009, Investigation of the in vitro metabolism of the analgesic flupirtine, Drug Metab Dispos, 37, 479, 10.1124/dmd.108.024364 · DOI
  8. Siegmund, 2015, Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1, Br J Clin Pharmacol, 79, 501, 10.1111/bcp.12522 · DOI
  9. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
  10. Urban, 2012, Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs, Pharmacogenet Genomics, 22, 784, 10.1097/FPC.0b013e3283589a76 · DOI · Paper page
  11. Pirmohamed, 2007, Investigation into the multidimensional genetic basis of drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics, 8, 1661, 10.2217/14622416.8.12.1661 · DOI
  12. Rothman, 2010, A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci, Nat Genet, 42, 978, 10.1038/ng.687 · DOI · Paper page
  13. Daly, 1996, CYP2D6 multiallelism, Methods Enzymol, 272, 199, 10.1016/S0076-6879(96)72024-4 · DOI
  14. Delaneau, 2013, Improved whole-chromosome phasing for disease and population genetic studies, Nat Methods, 10, 5, 10.1038/nmeth.2307 · DOI · Paper page
  15. Marchini, 2010, Genotype imputation for genome-wide association studies, Nat Rev Genet, 11, 499, 10.1038/nrg2796 · DOI · Paper page
  16. Zheng, 2014, HIBAG – HLA genotype imputation with attribute bagging, Pharmacogenomics J, 14, 192, 10.1038/tpj.2013.18 · DOI · Paper page
  17. Price, 2006, Principal components analysis corrects for stratification in genome-wide association studies, Nat Genet, 38, 904, 10.1038/ng1847 · DOI · Paper page
  18. Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet, 81, 559, 10.1086/519795 · DOI · Paper page
  19. Aithal, 2015, HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds, Hepatology, 62, 324A
  20. Daly, 2015, Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations, Drug Metabol Personal Ther, 30, 165, 10.1515/dmdi-2014-0034 · DOI
  21. Kringen, 2014, Serum bilirubin concentration in healthy adult North-Europeans is strictly controlled by the UGT1A1 TA-repeat variants, PLoS One, 9, e90248, 10.1371/journal.pone.0090248 · DOI
  22. Urban, 2014, Genetic basis of drug-induced liver injury: present and future, Semin Liver Dis, 34, 123, 10.1055/s-0034-1375954 · DOI · Paper page
  23. Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
  24. Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat Genet, 42, 711, 10.1038/ng.632 · DOI · Paper page
  25. Noble, 1996, The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families, Am J Hum Genet, 59, 1134
  26. Hollenbach, 2015, The immunogenetics of multiple sclerosis: a comprehensive review, J Autoimmun, 64, 13, 10.1016/j.jaut.2015.06.010 · DOI · Paper page
  27. Kindmark, 2008, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis, Pharmacogenomics J, 8, 186, 10.1038/sj.tpj.6500458 · DOI · Paper page
  28. Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379 · DOI · Paper page
  29. Hirata, 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study, Pharmacogenomics J, 8, 29, 10.1038/sj.tpj.6500442 · DOI · Paper page
  30. Kim, 2015, Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury, Hepatology, 62, 887, 10.1002/hep.27912 · DOI · Paper page
  31. Lucena, 2006, Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain, Hepatology, 44, 850, 10.1002/hep.21324 · DOI · Paper page
  32. Monshi, 2013, Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury, Hepatology, 57, 727, 10.1002/hep.26077 · DOI · Paper page
  33. Illing, 2012, Immune self-reactivity triggered by drug-modified HLA-peptide repertoire, Nature, 486, 554, 10.1038/nature11147 · DOI · Paper page
  34. Hautekeete, 1999, HLA association of amoxicillin-clavulanate – induced hepatitis, Gastroenterology, 117, 1181, 10.1016/S0016-5085(99)70404-X · DOI · Paper page
  35. Lucena, 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex, Hepatology, 49, 2001, 10.1002/hep.22895 · DOI · Paper page
  36. Li, 2008, Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial, Curr Med Res Opin, 24, 3523, 10.1185/03007990802579769 · DOI

Cited by

See all 79

Metadata

Authors
Nicoletti, P., Werk, A. N., Sawle, A., Shen, Y., Urban, T. J., Coulthard, S. A., Bjornsson, E. S., Cascorbi, I., Floratos, A., Stammschulte, T., Gundert-Remy, U., Nelson, M. R., Aithal, G. P., & Daly, A. K.
Venue
Pharmacogenetics and Genomics
Published
2016-05
Volume
26
Issue
5
Pages
218-224
ISSN
1744-6872 (ISSN-L)
OpenAlex
W2466633910
Cited by
79
References
3
FWCI
14.07
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HLA-DRB1*16: 01-DQB1*05 02 is a novel genetic risk factor for flupirtine-induced liver injury. https://app.cochat.ai/papers/10.1097/fpc.0000000000000209
The paper
Nicoletti, P., Werk, A. N., Sawle, A., Shen, Y., Urban, T. J., Coulthard, S. A., Bjornsson, E. S., Cascorbi, I., Floratos, A., Stammschulte, T., Gundert-Remy, U., Nelson, M. R., Aithal, G. P., & Daly, A. K. (2016). HLA-DRB1*16: 01-DQB1*05 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenetics and Genomics. https://doi.org/10.1097/fpc.0000000000000209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.